Literature DB >> 18329366

Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.

Masahiro Shinohara1, Takako Koga, Kazuo Okamoto, Shinya Sakaguchi, Kimiko Arai, Hisataka Yasuda, Toshiyuki Takai, Tatsuhiko Kodama, Tomohiro Morio, Raif S Geha, Daisuke Kitamura, Tomohiro Kurosaki, Wilfried Ellmeier, Hiroshi Takayanagi.   

Abstract

Certain autoimmune diseases result in abnormal bone homeostasis, but association of immunodeficiency with bone is poorly understood. Osteoclasts, which derive from bone marrow cells, are under the control of the immune system. Differentiation of osteoclasts is mainly regulated by signaling pathways activated by RANK and immune receptors linked to ITAM-harboring adaptors. However, it is unclear how the two signals merge to cooperate in osteoclast differentiation. Here we report that mice lacking the tyrosine kinases Btk and Tec show severe osteopetrosis caused by a defect in bone resorption. RANK and ITAM signaling results in formation of a Btk(Tec)/BLNK(SLP-76)-containing complex and PLCgamma-mediated activation of an essential calcium signal. Furthermore, Tec kinase inhibition reduces osteoclastic bone resorption in models of osteoporosis and inflammation-induced bone destruction. Thus, this study reveals the importance of the osteoclastogenic signaling complex composed of tyrosine kinases, which may provide the molecular basis for a new therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329366     DOI: 10.1016/j.cell.2007.12.037

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  124 in total

1.  Interleukin-33 stimulates formation of functional osteoclasts from human CD14(+) monocytes.

Authors:  Se Hwan Mun; Na Young Ko; Hyuk Soon Kim; Jie Wan Kim; Do Kyun Kim; A-Ram Kim; Seung Hyun Lee; Yong-Gil Kim; Chang Keun Lee; Seoung Hoon Lee; Bo Kyung Kim; Michael A Beaven; Young Mi Kim; Wahn Soo Choi
Journal:  Cell Mol Life Sci       Date:  2010-06-08       Impact factor: 9.261

2.  Locus category based analysis of a large genome-wide association study of rheumatoid arthritis.

Authors:  Jan Freudenberg; Annette T Lee; Katherine A Siminovitch; Christopher I Amos; David Ballard; Wentian Li; Peter K Gregersen
Journal:  Hum Mol Genet       Date:  2010-07-16       Impact factor: 6.150

3.  Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development.

Authors:  Kaori Tsuji-Takechi; Takako Negishi-Koga; Eriko Sumiya; Akiko Kukita; Shigeaki Kato; Takahiro Maeda; Pier Paolo Pandolfi; Keiji Moriyama; Hiroshi Takayanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 4.  Calcium signaling in osteoclasts.

Authors:  Sung-Yong Hwang; James W Putney
Journal:  Biochim Biophys Acta       Date:  2010-11-11

5.  Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.

Authors:  Bing Xia; Fulian Qu; Tian Yuan; Yizhuo Zhang
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

Review 6.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 7.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

8.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 9.  Cross-regulation of signaling by ITAM-associated receptors.

Authors:  Lionel B Ivashkiv
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

10.  Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.

Authors:  Rakesh Bam; Wen Ling; Sharmin Khan; Angela Pennisi; Sathisha Upparahalli Venkateshaiah; Xin Li; Frits van Rhee; Saad Usmani; Bart Barlogie; John Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2013-03-28       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.